Company profile
Fulcrum Therapeutics, Inc.
NASDAQ: FULC · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
58CFH 72DQ 69GM 3SS 43
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$74.9M
Employees
9
as of 2026-08-13
Market cap
$283.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$74.9M-$74.9M2025
Operating income-$84.8M-$84.8M2025
Total assets$366.3M$366.3M2025
Liabilities$17.3M$17.3M2025
Equity$349.0M$349.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Fulcrum Therapeutics, Inc.’s revenue?
Fulcrum Therapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Inhibikase Therapeutics, Inc.43DZentalis Pharmaceuticals, Inc.40DEledon Pharmaceuticals, Inc.39DALX Oncology Holdings Inc.37DCytoDyn Inc.30DCapricor Therapeutics, Inc.57CNeighbors
Middlesex →Key facts
CEOAlexander C. Sapir
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: FULC
Employees9
IPO date2019-07-18
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.